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This article intends to cover two aspects of non-segmen-
ted negative sense RNA viruses. In the initial section, the 
strategy employed by these viruses to replicate their 
genomes is discussed. This would help in understand-
ing the later section in which the use of these viruses 
as vaccine vectors has been discussed. For the descrip-
tion of the replication strategy which encompasses  
virus genome transcription and genome replication car-
ried out by the same RNA dependent RNA polymerase 
complex, a member of the prototype rhabdovirus fam-
ily – Chandipura virus has been chosen as an example 
to illustrate the complex nature of the two processes 
and their regulation. In the discussion on these viruses 
serving as vectors for carrying vaccine antigen genes, 
emphasis has been laid on describing the progress 
made in using the attenuated viruses as vectors and a 
description of the systems in which the efficiency of 
immune responses has been tested. 
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INFECTIOUS disease causing human deaths is an alarming 
issue for every country. Looking at the statistics provided 
by the World Health Organization (WHO) it is quite clear 
that emergence of new viruses along with the transformed 
strains of older ones is causing pandemics in recent years. 
Although a great majority of these deaths occur in devel-
oping countries, infectious diseases are not confined by 
international borders and therefore present a substantial 
threat to populations in all parts of the world. In recent 
years, the threat posed by infectious diseases has grown. 
New diseases, unknown in the United States just a decade 
ago, such as West Nile virus and severe acute respiratory 
syndrome (SARS), have emerged, and known infectious 
diseases once considered to have declined have reap-
peared with increased frequency. Furthermore, there is 
always the potential for an infectious disease to develop 
into a widespread outbreak, which could have significant 
consequences. Spreading of the disease is the regulatory 
factor of infectious disease. Infectious diseases are mostly 
spread either with the help of intermediate vectors or by 
air/water contamination. Vector-borne diseases are some-
times localized due to lack of proper vectors elsewhere. 
But the global changes in climate along with the ability 
of pathogens to adapt to similar kind of vectors allow the 
disease to spread globally. Haematophagous arthropod 
vectors such as mosquitoes, ticks and flies are responsible 
for transmitting bacteria, viruses and protozoa between 
vertebrate hosts, causing deadly diseases such as malaria, 
dengue fever and trypanosomiasis. In recent years, vari-
ous viral diseases have posed a great threat to the Indian 
subcontinent; Japanese encephalitis, the West Nile virus, 
Chandipura virus (CHPV), avian influenza (H5N1) and 
swine influenza (H1N1) being prominent among these. 
 The list of emergent viruses continues to grow. In the 
early 1990s, there was human immunodeficiency virus 
(HIV), Ebola, Lassa and others, almost all having jumped 
from their natural host species to humans. More recently, 
hepatitis C, Sin Nombre, West Nile, and of course SARS 
have emerged. A number of important human diseases, 
both established (mumps, measles, rabies) and emerging 
(Ebola haemorrhagic fever, Borna disease, Hendra virus, 
Nipah virus), are caused by viruses with RNA as their 
genome. 
 Among all the viruses, the RNA viruses pose special 
threats to the human population due to their ability to  
mutate very rapidly. They cause problems to the immune 
system as well as the vaccination and antiviral drug therapy. 
One of the orders of such RNA viruses is Mononegavi-
rales, that have non-segmented, negative sense RNA 
genome. The order includes four families: 
 
• Bornaviridae (Borna disease virus) 
• Rhabdoviridae (e.g. rabies virus) 
• Filoviridae (e.g. Marburg virus, Ebola virus) 
• Paramyxoviridae (e.g. Newcastle disease virus, measles 
virus). 
In order to combat the propagation of viral disease, anti-
viral drugs and vaccination are the two most potent 
therapies. Vaccination with live viruses began dated way 
back in 1983, when recombinant vaccinia virus express-
ing hepatitis B surface antigen demonstrated specific  
antibody production in immunized rabbits1. In general, 
live attenuated version of virus is a preferred choice for 
vaccination due its ability to express a full array of viral 
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Figure 1. Organization of the rhabdovirus particle. a, Electron microscope picture of rhabdovirus. b, Cartoon of the assembly of 
the viral proteins with RNA to form the virus. c, EM picture of the RNP particles. d, Cartoon of the RNP constituents. e, Genome 
organization of rhabdoviruses.  
 
 
antigens. However, in some cases we cannot use live  
attenuated viruses for immunization, e.g. viruses that do 
not grow well in vitro or the viruses that can exchange 
genes with circulating viruses. In these cases an alternative 
mode of vaccination is used which delivers only a com-
ponent of the viral antigen carried by a vector capable of 
replicating itself without damaging host and also allows 
high titer of antibody to antigen so that it can induce  
immune response. The vector used in this regard is mostly 
virus derived. Initially the DNA/positive sense RNA  
viruses are explored for their ability to act as vectors, but 
the non-segmented negative sense RNA viruses (NNSVs) 
have not been explored largely due to their inability to 
incorporate their genome RNA inside the cell culture and 
also due to lack of recombination mechanisms. But on the 
contrary, the NNSVs have some features that make them 
attractive candidates for vectors. Some animal/avian 
NNSV are antigenically distinct from human pathogens 
and hence they can infect the entire human population for 
successful immunization. NNSV can also replicate in 
cells like Vero cells which can be used in humans. Most 
importantly, the delivery of the vaccine can be effectively 
done via intranasal (IN) route and can elicit local immu-
noglobulin A and systemic immunoglobulin G and cell 
mediated protective immune response1. Genetic exchange 
is a rare event in NNSV and lack of recombinations with 
the circulating viruses make this a great vector. 
 Advent of reverse genetics changed the whole scenario 
regarding the use of viral vectors. We can now make 
cDNA clones of NNSV and transfect the construct within 
the cell along with some essential viral components to 
form a functional nucleocapsid. The viral antigen gene 
can either be integrated in the genome construct or the  
viral gene can replace one of the NNSV genes making a 
chimera. Vesicular stomatitis virus (VSV), a member of 
NNSV, has a number of advantages when used as vaccine 
vector. It has a very high level of expression associated 
with a rapid and efficient replication in vitro2. The VSV 
glycoprotein has three different serotypes that can be 
available for sequential immunization3,4. In experimental 
animals, VSV vectors can be administered by IN, intra-
dermal, intramuscular or oral route5–7. Also the virus has 
a regular structure that is stable facilitating purification 
and manufacturing processes6. 
 Since VSV is a prototype virus for NNSVs, which are 
increasingly being employed as vaccine vectors, the fol-
lowing overview provides the strategy followed in rhab-
doviruses, with specific example of CHPV for replication 
of its genome and also provides some insight into the 
complex processes of transcription of the genome by 
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Figure 2. Cartoon depicting the viral life cycle: decision making of viral transcription/replication by viral RdRp with the 
help of viral P protein. 
 
 
the same enzyme versus replication of the same genome 
by the same enzyme. 
 Rhabdoviruses belong to the mononegalovirales whose 
linear single-strand genome RNA has negative polarity; 
i.e. their genome RNA is noninfectious and complemen-
tary to functional, virus-specific, positive sense messenger 
RNAs (mRNAs). These characteristically bullet-shaped 
viruses are ubiquitous in nature and have a uniquely 
broad and diverse host range including vertebrates, inver-
tebrates and plants. Two notable and often studied rhab-
doviruses are the animal pathogen VSV and the human 
pathogen rabies virus (RV). One of the unique features of 
the negative-strand genome RNA of a rhabdovirus is that 
it serves as the template for both transcription (mRNA 
synthesis) and replication (genome RNA synthesis). More-
over, due to the packaging of a novel, virus-specified 
RNA polymerase within rhabdovirions, these viruses 
serve as one of the model systems to study transcription 
and replication and their regulation in vitro (Figure 1). 
 CHPV belongs to Vesiculovirus genera of the Rhab-
doviridae family within the order Mononegaloviridae. 
The RNA genome serves as a template for both transcrip-
tion as well as replication for these rhabdoviruses. CHPV 
genome RNA comprises a short 49 nt leader gene8,  
followed by five transcriptional units coding for viral 
polypeptides separated by intragenic spacer regions and a 
short non-transcribed 46 nt trailer sequence (t) arranged 
in the order 3′ l-N-P-M-G-L-t 5′. Upon infection, the  
virus releases its genome in host cytosol where it undergoes 
both transcription as well as replication. The viral RNA 
dependent RNA polymerase, large protein L, transcribes 
and replicates with the help of phosphoprotein P. Tran-
scription initiates at the 3′ end of the encapsidated genome, 
resulting in the synthesis of all the six viral mRNAs with 
progressive termination at each gene junction5,6,8. One of 
the key features of the rhabdoviruses is the polar nature 
of transcription. In the replication mode, the same RNA 
polymerase copies the entire genome to produce a posi-
tive stranded polycistronic RNA strand complementary to 
the whole viral genome. This positive sense RNA is used 
as template for subsequent synthesis of negative stranded 
progeny RNAs (Figure 2). Transcription and replication 
events depend on whether RNA polymerase can read-
through the gene boundaries or not. Termination of the 
products at gene boundaries leads to transcription, 
whereas anti-termination gives the replication product. 
 Vesiculovirus transcription is characterized by actino-
mycin D resistant synthesis of leader RNA and viral 
mRNAs. Order of transcription of VSV genes was deter-
mined by in vitro transcriptional mapping analysis using 
UV-radiation. Such studies revealed that VSV mRNAs 
are synthesized in an obligatory sequential manner after 
polymerase entry at single 3′ end of the genome termini, 
i.e. at the beginning of leader gene2,4,8. Determination of 
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relative molar ratios of different viral mRNAs within  
infected cells revealed that their abundance decreased 
with increasing distance from the 3¢ promoter in an order 
(N > P > M > G > L), thus implying a mechanism that 
also ensures polar transcription8. 
 Successful in vitro reconstitution of CHPV transcrip-
tion with purified components was shown by Chat-
topadhyay et al.9 and considered as an important step 
towards developing mechanistic insight into transcription. 
When purified, L protein was incubated with N-RNA in a 
reaction mixture that allows in vitro transcription, it was 
unable to synthesize viral mRNA. However, addition of 
viral P protein along with L allowed viral mRNA synthe-
sis. These studies confirmed the role of phosphoprotein 
as an activator of viral transcription9 and this proposed 
function was consistent in the observations made in 
VSV4. Unphosphorylated P undergoes phosphorylation 
with CKII and this phosphorylation induces P to form 
dimers. This phosphorylated P protein interaction with  
viral polymerase L results in active transcription9. P in its 
unphosphorylated form is capable of RNA binding and 
this binding is reversible in nature whereas phosphory-
lated P is not capable of RNA binding8. With the change 
in phosphorylation state, P regulates viral replication. It 
can be possible that this dual role of P is due to confor-
mational change induced by phosphorylation. P under-
goes phosphorylation in a stepwise manner. First, the 
serine-62 gets phosphorylated and this phosphorylated P 
undergoes phosphorylation again either by viral L protein 
associated kinase (LAK)10 or by host kinase10. The first 
step of the phosphorylation, i.e. the serine phosphoryla-
tion plays the most crucial role in determining P mediated 
transcription. Mutation in serine does not result in phos-
phorylation indicating that the conformational change in 
P protein during the first phosphorylation step allows the 
second site for phosphorylation. It was proposed that  
unphosphorylated P protein might play a role in viral rep-
lication by changing the polymerase to read-through the 
gene boundaries. To test this hypothesis, the virus yield 
was compared in infected cells overexpressing either wild 
type P protein or the mutant P lacking the CKII phos-
phorylation site. The virus titer was 100-fold more in the 
mutant than the wild type P, supporting the hypothesis. 
 In vitro transcription assay with detergent disrupted  
virus in presence of either wild type or phosphorylation 
defective P protein showed that phosphorylation favours the 
production of small leader RNA whereas unphosphory-
lated P protein favours the production of higher length 
RNAs at the expense of the small leader RNA11. 
 The role of the RNP particle structure in deciding the 
transcription of rhabdoviruses may also shed some light. 
If we compare the genome sequence of the VSV and 
CHPV, we will find some similarities at the gene termini 
as well as the intergenic regions. An interesting feature of 
the nucleotide sequence of the VSV genome is the inter-
genic sequence. Genes N, NS, M, G and L contain com-
mon sequences at their termini and between each other: 
5′CUGUUAGUUUUUUUCAUA3′ (ref. 8). Thus, the 
signal for termination, polyadenylation and initiation of 
RNA chains may reside within this sequence. The (U7) 
stretch clearly signifies the region where the polymerase 
probably ‘chatters’ to synthesize poly(A)7. Another  
important feature of the nucleotide sequence of the VSV  
genome is the end of the L gene and the 5′ end of genome 
RNA. It contains the same termination and polyadenyla-
tion signals but lacks the signal for downstream initiation. 
Therefore, the last 60 nucleotides, or trailer sequence, on 
the genome remain untranscribed in vitro. However, read-
through products containing L mRNA linked to the com-
plement of the end of genome RNA have been detected in 
vivo12, indicating that the entire genome is transcribed 
when the transcriptase is in a replicative mode. Another 
interesting feature is the presence of adenineuridine (AU)-
rich sequences sequestered in specified regions of  
genome RNA8. These sequences may be analogs of the 
TATA boxes which are located upstream of certain genes 
of eukaryotic DNA and which represent the promoter 
sites for RNA polymerase II. There are five such boxes in 
the VSV genome RNA, one of which resides in the middle 
of the leader template and others which reside near the 3′ 
ends of genes N, NS, M and G. The sequence within the 
leader template curiously coincides with one of the obser-
ved binding sites of the NS protein on the genome 
RNA11. Thus, it may be speculated that the other AU-rich 
sequences may also represent binding sites of the RNA 
polymerase complex from which it initiates RNA tran-
scription of downstream genes. 
 Construction of recombinant vaccinia virus expressing 
hepatitis B surface antigen by Smith et al.1 in 1983 is the 
beginning of the era of live viral vectored vaccines. They 
demonstrated the induction of hepatitis B-specific anti-
bodies in rabbits immunized with the recombinant virus. 
Subsequently, live-virus vectors were developed with 
other DNA viruses, such as adenoviruses and herpesvi-
ruses, and with positive-strand RNA viruses, such as  
alphaviruses and flaviviruses. Potentiality of the large 
group of NNSV has remained unexplored largely due  
to the lack of infectivity of their genomic RNA in cell  
culture and the absence of a mechanism for insertion of  
foreign genes. The NNSV (order Mononegavirales) com-
prise four families: Paramyxoviridae, including measles 
virus (MV) and mumps virus, Sendai virus (SeV), human 
parainfluenza virus types 1, 2, 3 and 4 (HPIV1 to -4), 
Newcastle disease virus (NDV), and human respiratory 
syncytial and metapneumoviruses (HRSV and HMPV); 
Rhabdoviridae, represented by VSV and RV; Filoviridae, 
containing Ebola and Marburg viruses; and Bornaviridae, 
containing Borna disease virus. Schnell et al.13 developed 
a reverse genetic system in 1994 for rhadoviruses that  
allowed the recovery of infectious virus entirely from 
cloned cDNA2. This approach was followed for numerous 
other NSNV14–22. 
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Scope of using NSNV as vectors for vaccine  
development 
Live attenuated viral pathogen is the best choice for a 
vaccine candidate, because it expresses the complete  
array of antigenic profile and elicits both local and sys-
temic immunity thereby providing solid protection against 
infection. However, there are several situations in which 
production of attenuated vaccines becomes impossible 
and production of vectored vaccine becomes necessary. 
(i) Attenuation of the virus is not possible; for example, 
HIV, due to its ability to establish a persistent infection, 
or Ebola virus, due to its high pathogenicity, (ii) viruses 
that fail to grow in vitro in cell culture system, such as 
human papillomavirus and hepatitis C virus, (iii) highly 
pathogenic viruses that pose safety problems during  
vaccine development, such as SARS coronavirus (SARS-
CoV) and Ebola virus, (iv) viruses that are highly labile 
due to physical instability and loss of infectivity, such as 
HRSV and (v) viruses that are reported to undergo recom-
bination with circulating viruses, such as CoVs, influenza 
viruses and enteroviruses. Alternative vaccines that can 
match with the use of attenuated pathogens as vaccines 
are to be employed. Viral vectored vaccine may overcome 
these specific challenges. In addition, they can be tailor-
made to include features that might improve efficacy, 
such as the targeting of dendritic cells23. In case of SeV 
based vector, the antigen gene could be efficiently  
expressed in dendritic cells by deleting gene for matrix 
protein. A known major advantage of a vectored vaccine 
is that it can be rapidly engineered to generate a vaccine 
against a newly emerged highly pathogenic virus. How-
ever in this case, sequence analysis of the new pathogen 
would identify the likely protective antigen(s), and its 
cDNA clones would be inserted into a vector for using as 
vaccine. 
 NNSV have a number of features that make them good 
viral vectors, some of them are described here. 
 
• The presence of are numerous well-characterized ani-
mal, avian and human NNSV that could serve as vec-
tors. Some avian or animal NNSV, such as NDV and 
VSV are antigenically distinct from common human 
pathogens and therefore essentially the entire popula-
tion should be susceptible to infection and successful 
immunization. Some of the human NSNV, such as 
HPIV1 to -3 also have the potential to be used as  
vaccine vectors in susceptible populations. For exam-
ple, infants and young children characteristically are 
immunologically naive to the three HPIV serotypes; 
thus, attenuated versions of HPIV1 to -3 can be deve-
loped as paediatric vaccine vectors. 
• Attenuation strategies for NNSV have been studied. In 
some cases, for example, animal or avian viruses are 
attenuated in primates due to a natural host range  
restriction. In other cases, mutations that cause attenua-
tion can be generated by reverse genetics before using 
as vectors. Thus, it should be possible to attenuate 
each viral vector expressing a foreign viral protective 
antigen such that it becomes safe and at the same time 
helps in eliciting desired immune response against the 
target antigen for the target population.  
• Several NSNV that have the potential to emerge as 
vaccine vectors replicate efficiently in known well-
characterized cell lines, such as Vero cells that are 
qualified for human and veterinary use which is a  
requirement for vaccine manufacture. 
• The efficient IN route of infection for most of the 
NNSV helps in efficient induction of local immu-
noglobulin A and systemic immunoglobulin G anti-
body and cell-mediated protective immune responses. 
This helps in the development of needle-free IN  
vaccines which could be administered easily and 
safely, facilitating immunization in the context of an 
outbreak or epidemic. IN vaccines are particularly 
useful against viruses like SARS-CoV and influenza, 
that spread via the respiratory tract. 
• NNSV replicate in the cytoplasm and hence there is 
no risk of integration of its genome with the host  
genome, obviating concerns about cellular transforma-
tion. 
• Gene exchange has not been observed in nature in 
NNSV24, indicating that the use of NNSV based  
vectored vaccines in open populations would not pose 
a threat of recombination between vaccine virus and 
circulating viruses. 
• The lack of recombination also contributes to the sta-
bility of the inserted foreign gene. 
• NNSV encode 5–11 separate proteins, while large 
DNA viruses, such as poxviruses, encode as many as 
200 proteins. Several proteins expressed by these 
complex viruses modulate or antagonize host immune 
responses, which might decrease vaccine effective-
ness. However there are reports that one or two pro-
teins that are encoded by most of the NNSV interfere 
with the host interferon system25,26, but these can often 
be mutated or deleted27–29. MV is one NNSV that is 
significantly immunosuppressive (mediated by a 
mechanism other than interferon antagonism), making 
it a less attractive vector candidate. In addition, the 
use of a complex vector that expresses a large number 
of proteins might be less desirable, since these vector 
antigens might dilute the desired antibody and cell-
mediated response directed against the foreign antigen 
and lead to a reduction of the overall memory  
T-cell pool29. 
• The genomes of NNSV consist of genes that for the 
most part are non-overlapping and are expressed as 
separate mRNAs, thus constituting a modular organi-
zation that can be readily manipulated for the insertion 
and stable maintenance of foreign inserts.  
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Preparation of infectious clones 
The first and foremost step while producing vectors from 
negative strand RNA viruses is generation of infectious 
cDNA clones. NNSV can be rescued entirely from cloned 
cDNA by transfecting cultured cells with plasmids encod-
ing the components of a nucleocapsid, i.e. (i) full-length 
genomic or antigenomic RNA and (ii) the proteins  
involved in transcription and replication, namely the nu-
cleoprotein (N or NP), phosphoprotein (P) and the large 
polymerase protein (L). However, in the case of HRSV 
and Filoviridae members, Marburg or Ebola viruses; in 
addition to components of nucleocapsid, the transcription 
elongation factor M2-1 or transcription activator factor 
VP30 respectively30–32 are needed for recovery. It is  
essential that transfection has to be done into a cell line 
that can support replication of the particular virus. The 
expression of the delivered plasmids can be done by bac-
teriophage T7 RNA polymerase that can be delivered in 
any of the three ways, i.e. by coinfection with a recombi-
nant vaccinia virus expressing T7 polymerase33; the use 
of cells that constitutively express T7 polymerase (pre-
sently baby hamster kidney cell line is available); or by  
co-transfection of a plasmid encoding T7 polymerase34. 
The third method is ideal and preferable, because it allows 
the recovery of viruses in a cell line approved for vaccine 
production (e.g. Vero or BHK) without adding any com-
ponent/s that needs regulatory approval (e.g. vaccinia  
virus). Intracellular expression of the genomic RNA and 
protein components of nucleocapsid results in the assem-
bly of a viral nucleocapsid which is competent for gene 
expression and genome replication, resulting in produc-
tion of infectious virus. Once the infective cDNA is 
available, several strategies can be employed to generate 
vaccines. Some of the most important ones are described 
here. 
Production of vaccines using  
replication-competent NNSV 
The simplest strategy is to express one or more foreign 
antigens from genes that have been added to a complete, 
replication-competent NNSV35. The NNSV vector must 
be sufficiently attenuated to be safe for administration to 
humans. In the case of NNSV, such as NDV, that are  
attenuated in primates due to a natural host restriction36, 
the wild-type virus can be used directly as vector. Other 
NNSV will require attenuation by reverse genetics before 
use as potential vectors in humans. For example, VSV  
is not a common human pathogen, but VSV infection is  
associated with disease which may not be serious in  
humans37. Thus, attenuation is needed before VSV can be 
used as a vaccine vector. Similarly HPIV3, which can 
cause respiratory infection in humans, needs to be attenu-
ated and validated. 
 Attenuation of NNSV can be achieved by employing 
various strategies. The viral gene order can be rearranged, 
which results in a suboptimal level of gene expression 
and thereby reduces replication efficiency38. Point muta-
tions can be introduced in the known region by reverse 
genetics38,39. Mutations can also be ‘transferred’ between 
related viruses by reverse genetics using sequence align-
ments as a guide40–42. Deleting or silencing nonessential 
accessory genes, including those encoding interferon  
antagonist proteins, often yields attenuated derivati- 
ves43–45. In case of rhabdoviruses, an effective attenuation 
of replication without a significant reduction of immuno-
genicity could be achieved by partial truncation of the  
G glycoprotein cytoplasmic tail28,46–48. The insertion of 
foreign genes for expression frequently has an attenuating 
effect by itself. Attenuation can also be achieved by 
swapping internal protein genes between related human 
and animal or avian viruses to introduce host range  
restriction49,50. 
Production of chimeric viruses 
An alternative method to deliver foreign antigen is to  
replace the major protective surface antigen(s) of the 
vector with that of the pathogenic virus of interest. Such 
antigenic chimeric virus can be a viable vaccine vector 
provided the surface proteins of foreign origin are effec-
tively incorporated into the virion particles and becomes 
functional in the vector background.  
 Several notable examples are based on VSV in which 
the VSV G glycoprotein is replaced by the haemaggluti-
nin (HA) glycoprotein of influenza virus48 or the respec-
tive glycoprotein of Ebola, Marburg or Lassa virus51,52 
and Borna disease, a fatal immune-mediated neurological 
disease in sheep and horse caused by Borna disease  
virus53. The resulting chimeras were attenuated in vitro 
compared to the VSV parent, suggestive of a degree of 
incompatibility between vector proteins and foreign gly-
coproteins thereby increasing the safety of the vaccine. 
Although attenuated, the chimeras were competent for  
in vivo replication and were immunogenic and protective 
in mice or nonhuman primates48,51,52,54. However, not all 
VSV-based chimeras are replication competent. For  
example, chimeras in which the VSV G protein was  
replaced with the G or F protein of HRSV were not  
viable, even though each HRSV protein was incorporated 
into the VSV particle, and even though F alone is suffi-
cient to confer efficient infectivity and growth to HRSV 
in vitro55,56. 
 A noteworthy antigenic chimeric virus is the replace-
ment of the F and HN surface glycoprotein genes of  
bovine PIV3 (BPIV3), which is attenuated in humans due 
to a natural host range restriction, with the F and HN 
genes from its closely related human counterpart HPIV3. 
This has the effect of combining the host range restriction 
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of BPIV3 with the major antigenic determinants of 
HPIV3, resulting in an attenuated virus bovine–human 
PIV3 (B/HPIV3) that replicates with undiminished effi-
ciency in vitro, retains the host range attenuation pheno-
type in nonhuman primates, and is under clinical trials as 
a vaccine against HPIV3 (refs 57–59). 
 However, substitution of the HN and F glycoproteins of 
HPIV1 into an HPIV3 backbone resulted in a chimera 
that replicated with wild-type efficiency in vitro and in 
vivo41,59. The lack of attenuation associated with chimeri-
zation in this case reflects the close relationship between 
these two viruses. The substitution of the HN and F gly-
coproteins of the more-distantly related HPIV2 (genus 
Rubulavirus) into HPIV3 did not yield a viable chimeric 
virus. However, when the HN and F proteins of HPIV2 
were modified to replace their cytoplasmic domains with 
the corresponding ones of HPIV3, viable antigenic chime-
ras that replicated efficiently in vitro could be recovered, 
although they were attenuated in vivo60. Thus, the ability 
of a heterologous glycoprotein to function efficiently in 
an antigenic chimera may depend on the fit of its cyto-
plasmic domain into the vector background. 
Production of chimeric virus expressing  
additional foreign genes 
Antigenic chimeric viruses also can be used to express 
additional antigens from added genes of immunological 
importance. Thus one vaccine can be developed against 
several diseases. For example, the B/HPIV3 chimera has 
been used to express protective antigens of HRSV or 
HMPV from added genes61–63. These applications would 
yield a bivalent vaccine against HPIV3 and HRSV or 
HPIV3 and HMPV respectively, each based on a single 
virus. B/HPIV3 expressing the HRSV F glycoprotein is 
currently in clinical trials by Med Immune, Inc. 
Specific viral vaccine vectors 
Newcastle disease virus 
NDV (family Paramyxoviridae, subfamily Paramyxoviri-
nae, genus Avulavirus) is an avian pathogen which natu-
rally occurs as three pathotypes: velogenic strains, which 
cause systemic infections with a high level of mortality; 
mesogenic strains, which cause systemic infections of  
intermediate severity and lentogenic strains, which cause 
mild infections that are largely limited to the respiratory 
tract and which are used as live attenuated vaccines 
against NDV for poultry64. One of the primary determi-
nants of virulence is the cleavage activation phenotype of 
the F protein precursor, which in highly virulent strains is 
cleaved by ubiquitous intracellular proteases, providing 
the potential for pantropic replication, and which in  
nonvirulent strains is cleaved by a secretory protease,  
restricting replication to mucosal surfaces. NDV usually 
does not infect humans, but occasionally causes conjunc-
tivitis in bird handlers65,66. IN and IT inoculation of the 
respiratory tract of African green and rhesus monkeys 
with a mesogenic or lentogenic strain of NDV resulted in 
attenuation36 due to a natural host-range restriction. 
 NDV shares only a low level of amino acid sequence 
identity with human paramyxoviruses and is distinct anti-
genically, suggesting that the human population would be 
susceptible to vaccination with an NDV-based vector. 
Studies with mice showed that NDV expressing protec-
tive antigens of influenza A virus, HRSV or simian  
immunodeficiency virus (SIV) were immunogenic and, in 
the first two cases, induced protection against chal-
lenge19,67,68. However rodents are not good models for 
evaluation due to phylogenetic distance. Recently,  
recombinant lentogenic and mesogenic strains of NDV 
expressing HPIV3 HN protein from an added gene were 
evaluated by IN and IT immunization of the respiratory 
tract of African green monkeys and rhesus monkeys.  
After one dose, an efficient HPIV3-specific serum anti-
body response was detected; after the second dose, it  
became equal to or greater than that induced by HPIV3 
infection36. Thus, NDV warrants further evaluation as a 
potential vector for human use. NDV is also being  
actively developed as a vaccine vector for veterinary use 
in which the vector itself serves as a needed poultry  
vaccine69–71. NDV is classified as serotype 1 of the avian  
paramyxoviruses of genus Avulavirus; eight other sero-
types, which cause disease of various levels of severity in 
different species of birds have been identified72. These 
can also be evaluated as possible vectors for human use. 
Vesicular stomatitis virus 
VSV (family Rhabdoviridae, genus Vesiculovirus) is a 
natural pathogen of cattle, horses and swine that causes 
disease characterized by severe vesiculation and/or ulcera-
tion of tongue, oral tissues, feet and teats73. The infection 
of mice and cotton rats with VSV by the IN route results 
in significant replication of the virus in brain, encephalitis 
and high mortality74–76. VSV is not usually a human 
pathogen. Most human infections that do occur (from 
contact with infected animals) are believed to be asymp-
tomatic but sometimes result in illness characterized by 
chills, myalgia and nausea77–79. A case of encephalitis as-
sociated with VSV infection in a 3-year-old child has also 
been documented80. 
 VSV has a number of very advantageous features as 
vaccine vector; it is the simplest NSNV with extremely 
efficient replication and high level of expression in vitro. 
The general population in most areas of the world lacks 
immunity to VSV and thus, presumably, is susceptible to 
immunization. Recombinant VSV bearing the G glyco-
protein from three different serotypes is available for  
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sequential immunization81,82. In experimental animals, 
VSV vectors have been very effective when administered 
by the IN, IM, intradermal or oral routes83–85. 
 The major drawback for VSV is that, at present, there 
is little or no experience with its administration to humans 
and, thus, it is not clear whether serious complications 
may occur in some individuals. The central nervous sys-
tem involvement observed in rodents and a human case 
warrants caution. Also it is not known how immunogenic 
and protective VSV vectors will behave in humans, either 
as antigenic chimeric viruses or as vectors expressing 
added foreign genes, although results with experimental 
animals are promising. Recombinant VSV appears to be 
inherently attenuated, presumably due to chance muta-
tions, and a number of strategies exist for further attenuat-
ing the virus3. There is possibility that VSV-based 
vaccines will be evaluated clinically in the near future 
and, thus, detailed information on its replication, patho-
genesis and immunogenicity needs to be evaluated. 
 Though VSV is somewhat of an unknown entity at  
present with regard to human administration, it is belie-
ved that its most feasible first use will be as a vector to 
control outbreaks of highly pathogenic agents. This is  
because, the vaccination is done only for healthy adults, 
the number of vaccines will be relatively small, and the 
high risk of the pathogen would outweigh some potential 
risk of residual virulence of the vector3. As described ear-
lier, antigenic chimeras based on VSV expressing the GP 
glycoprotein of the haemorrhagic fever agents Ebola, 
Marburg or Lassa viruses have been constructed. A single 
IM immunization of cynomolgus macaques with the con-
structs was well tolerated and induced antibody and cellu-
lar immune responses specific to the foreign GP, which 
protected the animals against a subsequent challenge with 
a high dose of each respective virus52,54. VSV has also 
been used to express the SARS-CoV S spike glycoprotein 
from an added gene, and a single IN immunization of 
mice provided complete protection against an IN chal-
lenge with SARS-CoV85. As experience with VSV in 
humans is gained and safety and immunogenicity are  
established, another use in outbreak control would be to 
immunize against highly pathogenic H1N1 influenza or 
pathogenic H5N1 viruses in areas where those viruses are 
endemic or during pandemic situations. VSV bearing the 
HA glycoprotein of human influenza A virus was highly 
immunogenic and protective against an otherwise lethal 
challenge in mice86. In this application, the lack of  
recombination associated with NNSV provides a major 
safety advantage thus making prospective immunization 
feasible. 
 VSV has also been evaluated as a vaccine vector 
against a number of prevalent human viruses, including 
papillomavirus84,87, hepatitis C virus88 and HIV81–83,89. In 
particular, the three VSV glycoprotein exchange vectors 
were each engineered to express the SIV Gag protein and 
HIV-1 envelope protein from added genes. Three sequen-
tial immunizations of rhesus monkeys by the combined 
IM and oral routes induced a vigorous HIV-specific cyto-
toxic T lymphocyte (CTL) response and protection 
against a subsequent challenge with simian–human  
immunodeficiency virus (SHIV)81. This is an important 
line of experiments, since effective immunization against 
HIV poses the most daunting challenge to vaccinology. 
 VSV has also been developed as a vector against com-
mon paediatric pathogens, such as HRSV55 and MV79,90. 
However the use of these vaccines seems to be limited, 
since it would be preferable to avoid mass inoculation of  
infants with a virus that they otherwise would rarely  
encounter and for which immunoprophylaxis is not 
needed. This view might change if VSV is found to be 
substantially more effective in humans than live attenu-
ated versions for these paediatric pathogens. However, 
the use of VSV in a mass vaccination probably would in-
terfere with its subsequent use against other pathogens. 
Rabies virus 
RV (family Rhabdoviridae, genus Lyssavirus) causes 
deadly neurological diseases in numerous animal species 
and humans. Several highly attenuated strains of the virus 
lacking neurovirulence in experimental animals have been 
developed46,91–93. Studies with mice have demonstrated 
the immunogenicity of RV vectors expressing the HIV 
envelope or Gag protein, or SARS-CoV S protein, from 
added genes94–98. Since RV infection in humans is rare, 
most of the population would be susceptible to immuni-
zation with an RV-based vector. However, whether  
attenuated derivatives could be used in humans is unclear, 
given the high neurovirulence of the parent virus.  
Sendai virus 
SeV (family Paramyxoviridae, subfamily Paramyxoviri-
nae, genus Respirovirus) is a parainfluenza virus and 
shares a moderate level of sequence and antigenic relat-
edness with HPIV1 and virulent to mice. This antigenic 
relatedness is helpful in developing paediatric vaccine 
against HPIV1 on the premise that SeV will be attenuated 
in humans due to a host range restriction99–101. SeV has 
also been evaluated as a vector to express the HRSV G 
glycoprotein gene. This bivalent vaccine against HPIV1 
and HRSV upon IN inoculation of cotton rats induced 
HRSV-neutralizing antibodies and a high level of protec-
tion against a subsequent challenge with HRSV102. How-
ever, SeV replicated nearly as efficiently as wild-type 
HPIV1 in African green monkeys and chimpanzees, rais-
ing doubts as to whether it will be satisfactorily attenuated 
in unmodified form for use in seronegative humans100. 
 SeV expressing the SIV Gag gene was tested for  
immunogenicity and protective efficacy against SIV chal-
lenge. A group of 8 macaques was primed with a plasmid 
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DNA expressing SIV Gag and boosted with the SeV-Gag 
construct. Upon challenge with SIV by the intravenous 
route, 5 weeks after vaccination; 5 out of 8 vaccinated 
animals showed undetectable plasma viraemia103. The use 
of a recombinant SeV expressing SIV Gag for immuniza-
tion of macaques chronically infected with SIV resulted 
in the induction of an effective Gag-specific CTL  
response104. However, the use of SeV as a vaccine vector 
for the adult human population may pose problems due to 
its antigenic relatedness to HPIV1 and presence of anti-
bodies against HPIV1. Indeed, IN immunization of 
healthy human adult volunteers with SeV resulted in  
an increase in virus-specific antibodies in only three out 
of nine individuals, suggesting restricted replication due 
to previous exposure to HPIV1101. Therefore, further 
studies are needed to evaluate the level of attenuation and 
immunogenicity of SeV-based vaccines in HPIV1 sero-
negative and seropositive humans. 
Human parainfluenza viruses 
The HPIVs belong to family Paramyxoviridae, subfamily 
Paramyxovirinae, genus Respirovirus (HPIV1 and -3), 
and genus Rubulavirus (HPIV2 and -4). HPIVs cause res-
piratory illness in infants and children ranging from 
common cold to pneumonia and is prevalent worldwide. 
Live attenuated derivatives of HPIV1, -2 and -3 have 
been developed by reverse genetics for use as IN paediatric 
vaccines, whereas HPIV4 I is a less serious pathogen42,105. 
Thus, in contrast to VSV, there is extensive experience 
with infection of humans by HPIVs. HPIVs have a larger 
genome (15 kb vs 11 kb) than VSV. They are larger and 
pleomorphic, and encode two or more additional proteins. 
They replicate at least 10 to 100-fold less efficiently in 
cell culture. HPIVs infect and cause disease only in the 
respiratory tract and do not spread (significantly) to other 
tissues which limits HPIV-based vectors to IN admini-
stration. However this is a positive aspect with respect to 
safety. Upon IN immunization, it induces both strong  
systemic and local immunity. 
 The HPIVs are ideally suitable vectors for paediatric 
pathogens, especially for those that cause respiratory tract 
infections and use the tract as a portal of entry, e.g. mea-
sles virus, HRSV and HMPV. Since vaccines for HPIVs 
are needed, insertion of a protective antigen gene of  
another paediatric virus creates a bivalent vaccine, thus 
simplifying administration. For example, topical immuni-
zation of the respiratory tract of rhesus monkeys with an 
attenuated version of HPIV3 expressing the HA glycopro-
tein of MV efficiently induced systemic neutralizing anti-
body responses specific for both MV and HPIV3 (refs 
106 and 107). This method is beneficial in two ways: (i) 
The existing measles vaccine is a live attenuated virus 
that is administered IM and is very sensitive to neutraliza-
tion by maternal antibodies thereby necessitating a delay 
in administration until 12–15 months of age with the  
result that some individuals become susceptible before 
the vaccination is received. An HPIV3-vectored vaccine 
is not neutralized by MV-specific antibodies and can effi-
ciently infect and immunize young infants at an earlier 
age. (ii) The vaccine eliminates concerns of persistence 
or partial reversion of the live attenuated measles vaccine 
virus, facilitating a global effort to eradicate MV. How-
ever, it may take some time to replace the established, 
current live attenuated measles vaccine. 
 Similarly attenuated chimeric B/HPIV3 expressing the 
protective F or G protein of HRSV or the F protein of 
HMPV was shown to be immunogenic against both the 
vector and the vectored antigen in rodents and nonhuman 
primates61–63,108. In this case, the use of an HPIV-vectored 
vaccine results in a higher level of antigen expression and 
avoids the poor growth and instability of HRSV and 
HMPV. The attenuated B/HPIV3 virus expressing HRSV 
F is presently in clinical trials as a live IN vaccine against 
HPIV3 and HRSV. Vectored vaccine based on HPIV3 
would be most suitable for immunization within the first 
six months of life, whereas vectors based on HPIV1 and  
-2 would be most suited for immunization between six 
months and one year of age. 
 The HPIVs also have been evaluated as vectors against 
highly pathogenic viruses that can infect via the respira-
tory tract. IN and IT immunization of African green mon-
keys with an attenuated B/HPIV3 virus expressing the 
spike (S) protein of the respiratory pathogen SARS-CoV 
resulted in the induction of a systemic neutralizing anti-
body response against SARS-CoV and conferred protec-
tion against IN and IT challenge with SARS-CoV109. 
HPIV3 was also used to express the GP glycoprotein of 
Ebola virus to evaluate the efficacy of IN immunization 
against a virus that causes a severe systemic infection. IN 
immunization of guinea pigs with this recombinant  
induced a systemic Ebola virus-specific antibody re-
sponse and conferred complete protection against a lethal 
dose of guinea pig-adapted Ebola virus administered  
intraperitoneally110; the construct is now being evaluated 
in nonhuman primates. These vaccine candidates could be 
developed for use as paediatric vaccines against SARS-
CoV and Ebola virus. However, its efficacy in adults due 
to natural infection with HPIV3 needs to be studied. Use 
of nonhuman paramyxoviruses, such as NDV as a vector 
may solve this problem. 
 MV is an important member of the Morbillivirus genus 
in the Paramyxoviridae family. Attenuated measles  
vaccine induces a life-long immunity which persists for a  
period as long as 25 years111. In addition, MV shows  
genetic stability upon multiple in vitro passages. The  
envelope glycoprotein gene of HIV has been cloned into 
MV vector and this has been shown to elicit high levels 
of CD8+ and CD4+ cells upon single immunization. In 
addition, the antibodies generated show virus neutralizing 
antibody titres112. 
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 In conclusion, while the results of immune response 
experiments with NNSV vectored vaccines are highly  
encouraging, this field is wide open for designing better-
priming vectors as well as for studying long term, robust 
immune responses elicited by combinations of differently 
primed and boosted vaccines. 
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